Six months into the 117th Congress, the U.S. Senate has recently increased its oversight activities following a slow start. Since April, newly empowered Democratic Members have launched or requested more than 20 inquiries...more
7/6/2021
/ Anti-Competitive ,
Biden Administration ,
Congressional Oversight ,
Coronavirus/COVID-19 ,
Cryptocurrency ,
Cybersecurity ,
Diversity and Inclusion Standards (D&I) ,
Drug Pricing ,
Food and Drug Administration (FDA) ,
Manufacturers ,
Pharmaceutical Industry ,
Popular ,
Relief Measures
On May 15, 2018, the Senate Committee on Health, Education, Labor and Pensions held a hearing entitled “Examining Oversight Report on the 340B Drug Pricing Program.” Led by Subcommittee Chairman Sen. Lamar Alexander (R-TN),...more
On October 11, 2017, the House Energy & Commerce’s Oversight and Investigations Subcommittee held a hearing entitled “Examining How Covered Entities Utilize the 340B Drug Pricing Program.” This was the Subcommittee’s second...more
On July 18, 2017, the House Energy & Commerce’s Oversight and Investigations Subcommittee held a hearing on “Examining HRSA’s Oversight of the 340B Drug Pricing Program.” The hearing featured a single panel of three federal...more